89 related articles for article (PubMed ID: 7556865)
1. Monoclonal antibody-defined lymphocyte subsets in cervical carcinoma.
Chen RJ; Huang SC; Hsieh CY
Int J Gynaecol Obstet; 1995 Jul; 50(1):67-8. PubMed ID: 7556865
[No Abstract] [Full Text] [Related]
2. Antibody dependent cell mediated cytotoxicity on human cervical carcinoma cell line, ME-180, with human monoclonal antibody.
Osumi K; Nagao J; Yuasa H; Fujimoto H; Hagiwara H; Kodera Y; Ohno R
Cancer Lett; 1992 Feb; 62(2):179-83. PubMed ID: 1540945
[TBL] [Abstract][Full Text] [Related]
3. Immunological abnormalities in patients with cervical carcinoma.
Castello G; Esposito G; Stellato G; Dalla Mora L; Abate G; Germano A
Gynecol Oncol; 1986 Sep; 25(1):61-4. PubMed ID: 3732919
[TBL] [Abstract][Full Text] [Related]
4. Cell-mediated cytotoxicity against HeLa cells in patients with invasive or preinvasive cervical cancer.
Saksela E; Meyer B
J Natl Cancer Inst; 1973 Oct; 51(4):1095-102. PubMed ID: 4745849
[No Abstract] [Full Text] [Related]
5. Decreased natural killer cell activity in patients with invasive cervical carcinoma.
Chou CY; Hsieh CY; Hsieh KH; Chen CA
Taiwan Yi Xue Hui Za Zhi; 1989 Feb; 88(2):128-31. PubMed ID: 2788713
[TBL] [Abstract][Full Text] [Related]
6. Cell-mediated immunity in invasive cervical carcinoma associated with human papillomavirus types 16 and 18 infection.
Park TK; Kim SN; Lee CH
Int J Gynaecol Obstet; 1994 Jul; 46(1):67-8. PubMed ID: 7805989
[No Abstract] [Full Text] [Related]
7. [Nonspecific immunologic response in grade II cervical cancer].
Rytwiński K; Schneiberg K; Cofalik A; Bartnikowa W; Tabeńska J
Nowotwory; 1980; 30(1):1-11. PubMed ID: 7393739
[No Abstract] [Full Text] [Related]
8. ["In vivo" and "in vitro" immunological monitoring in carcinoma of the uterine cervix].
Sacco F; Benedetti Panici P; Di Roberto P; Margariti PA; Villani L; Laghi V; Cauda R; Nervo P
Minerva Ginecol; 1982 Apr; 34(4):259-64. PubMed ID: 7048137
[No Abstract] [Full Text] [Related]
9. Antibodies to herpesvirus type 1 and type 2 among Japanese cervical cancer patients.
Ozaki Y; Ishiguro T; Ohashi M; Sawaragi I; Ito Y
Gan; 1978 Feb; 69(1):119-22. PubMed ID: 640320
[TBL] [Abstract][Full Text] [Related]
10. Cell-mediated cytotoxicity in vitro of human lymphocytes against a cervical cancer cell line.
Mashiba H; Matsunaga K; Ueno M; Jimi S
Gan; 1977 Feb; 68(1):53-8. PubMed ID: 558932
[TBL] [Abstract][Full Text] [Related]
11. Antibody-dependent cell-mediated cytotoxicity to herpes simplex virus type 2 infected target cells in the course of cervical carcinoma.
Christenson B
Am J Epidemiol; 1978 Aug; 108(2):126-35. PubMed ID: 101081
[TBL] [Abstract][Full Text] [Related]
12. [Suppression of cellular immunity in patients with carcinoma in situ and microinvasive cancer of the cervix uteri].
Marinova-Mutafchieva LP; Chakalova GB; Goranov IT
Vopr Onkol; 1991; 37(4):454-7. PubMed ID: 1832253
[TBL] [Abstract][Full Text] [Related]
13. A study of herpes simplex type 2 antibody status in groups of patients with cervical neoplasia in Czechoslovakia.
Janda Z; Kanka J; Vonka V; Svoboda B
Int J Cancer; 1973 Nov; 12(3):626-30. PubMed ID: 4364794
[No Abstract] [Full Text] [Related]
14. Lymphoid cell distribution as prognostic factor in carcinoma of the uterine cervix.
Onsrud M; Grahm I; Gaudernack G; Tropé C
Acta Obstet Gynecol Scand; 1992 Feb; 71(2):135-9. PubMed ID: 1316042
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibodies to herpesvirus types 1 and 2 in carcinoma of the cervix, carcinoma in situ and cervical dysplasia.
McDonald AD; Williams MC; Manfreda J; West R
Am J Epidemiol; 1974 Aug; 100(2):130-5. PubMed ID: 4368955
[No Abstract] [Full Text] [Related]
16. Immunohistochemical detection of the multi-drug-resistance marker P-glycoprotein in uterine cervical carcinomas and normal cervical tissue.
Schneider J; Efferth T; Mattern J; Rodriguez-Escudero FJ; Volm M
Am J Obstet Gynecol; 1992 Mar; 166(3):825-9. PubMed ID: 1372471
[TBL] [Abstract][Full Text] [Related]
17. The association of herpesvirus type 2 and carcinoma of the uterine cervix.
Rawls WE; Tompkins WA; Melnick JL
Am J Epidemiol; 1969 May; 89(5):547-54. PubMed ID: 5818824
[No Abstract] [Full Text] [Related]
18. Natural killer cell activity in patients with invasive cervical carcinoma: importance of a longitudinal evaluation in follow-up.
Garzetti GG; Ciavattini A; Muzzioli M; Goteri G; Mannello B; Romanini C; Fabris N
Gynecol Obstet Invest; 1995; 40(2):133-8. PubMed ID: 8575692
[TBL] [Abstract][Full Text] [Related]
19. [Preparation and characterization of monoclonal antibody against human uterine cervical carcinoma].
Song G
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1991 Apr; 13(2):137-40. PubMed ID: 1831711
[TBL] [Abstract][Full Text] [Related]
20. Herpesvirus type 2-induced, tumor-specific antigen in cervical carcinoma.
Aurelian L; Davis HJ; Julian CG
Am J Epidemiol; 1973 Jul; 98(1):1-9. PubMed ID: 4131112
[No Abstract] [Full Text] [Related]
[Next] [New Search]
